Detalles de la búsqueda
1.
Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nature;
566(7742): E1, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30659290
2.
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nature;
534(7605): 47-54, 2016 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27135926
3.
Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer.
BMC Cancer;
21(1): 815, 2021 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34266398
4.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet;
393(10191): 2591-2598, 2019 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31178155
5.
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Breast Cancer Res Treat;
177(3): 659-667, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31297647
6.
Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial.
BMC Cancer;
19(1): 737, 2019 Jul 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31345179
7.
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
Br J Cancer;
119(1): 76-79, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880907
8.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Breast Cancer Res;
19(1): 98, 2017 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28830573
9.
Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.
Breast Cancer Res Treat;
165(3): 611-621, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28685212
10.
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Lancet Oncol;
17(5): 600-11, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27032301
11.
Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
Int J Cancer;
139(10): 2299-311, 2016 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27464303
12.
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
PLoS Med;
13(12): e1002201, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28027327
13.
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Breast Cancer Res Treat;
156(2): 301-10, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26975189
14.
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
Breast Cancer Res Treat;
157(2): 307-318, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27167986
15.
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
BMC Cancer;
16: 428, 2016 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27387327
16.
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
BMC Cancer;
15: 986, 2015 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-26680641
17.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
Lancet Oncol;
15(11): 1269-78, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25273342
18.
Cancer-related fatigue in breast cancer patients after surgery: a multicomponent model using partial least squares-path modeling.
Psychooncology;
23(4): 444-51, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24150929
19.
Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.
Future Oncol;
10(2): 195-209, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24490606
20.
[uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management]. / uPA/PAI-1, Oncotype DX™, Mammaprint(®). Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein.
Ann Pathol;
34(5): 349-51, 2014 Oct.
Artículo
en Francés
| MEDLINE | ID: mdl-25439987